What is DNA Script?
Founded in 2014, DNA Script is a life sciences technology firm revolutionizing the design and manufacture of nucleic acids. The company's proprietary Enzymatic DNA Synthesis (EDS) technology offers a faster, more powerful, and versatile alternative to traditional chemical synthesis. By enabling DNA synthesis directly within laboratories via its SYNTAX System, DNA Script empowers researchers with unprecedented control and autonomy, aiming to transform life sciences research and development.
How much funding has DNA Script raised?
DNA Script has raised a total of $302M across 3 funding rounds:
Series A
$13M
Series B
$89M
Series C
$200M
Series A (2017): $13M with participation from Illumina Ventures
Series B (2020): $89M led by M Ventures, Bpifrance Large Venture Fund, Danaher Life Sciences, Illumina Ventures, Life Sciences Partners, Agilent Technologies, and Casdin Capital
Series C (2021): $200M supported by Catalio Capital Management and Coatue
Key Investors in DNA Script
M Ventures
M Ventures, the venture capital arm of Merck, focuses on investing in innovative technologies that can significantly impact core business areas. They actively support portfolio companies in translating innovation into commercial success, with a strong emphasis on early-stage investments.
Illumina Ventures
Illumina Ventures is a key player in genomics and precision health investment, dedicated to fostering an ecosystem that drives innovation in human health. They support companies advancing life science research, biopharmaceutical development, and gene editing.
Agilent Technologies
Agilent Technologies is a global leader providing advanced instruments, software, and services for life sciences, diagnostics, and applied markets. They support research, clinical diagnostics, and pharmaceutical development worldwide.
What's next for DNA Script?
The recent major strategic investment in DNA Script signals a new phase of accelerated growth and market expansion. This capital infusion is expected to fuel further innovation in enzymatic DNA synthesis, enhance production capabilities, and broaden the adoption of their technology across the global life sciences sector. The company is poised to solidify its leadership in enabling next-generation biological research and therapeutic development.
See full DNA Script company page
